Chi-Mei Medical Center

Tainan 73657

18 studies enrolling now · 58 studies all time

What they study most

Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder), Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Acute Myocardial Infarction, Acute Respiratory Failure, Adenocarcinoma of Lung, Advanced Gastrointestinal (GI) Malignancies, Advanced Hepatocellular Carcinoma, Advanced Solid Tumours, Advanced or Inoperable Gastric Cancer, Arthritis, Psoriatic, Atherosclerotic Cardiovascular Disease (ASCVD)

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis — Recruiting now
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — Recruiting now
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — Recruiting now
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — Recruiting now
• Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial — Recruiting now
• A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies — Recruiting now
• A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma — Recruiting now
• A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer — Recruiting now
• A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma — Running, not enrolling
• A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight — Withdrawn before enrolling
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) — Completed
• A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) — Completed
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
• Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies — Running, not enrolling
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec — Completed
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) — Completed
• Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling
• Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer — Completed
• IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer — Completed
• Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer — Stopped early
• A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study) — Completed
• Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease — Completed
• Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug — Completed
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus — Stopped early
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy — Stopped early
• Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma — Stopped early
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy — Stopped early
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes — Completed
• Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC — Stopped early
• CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer — Completed
• A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy — Completed